Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. September 2020 16:01 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

– Company announces organizational changes designed to accelerate global strategy – BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage...
09. September 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Investor Conferences in September

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of...
06. August 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference

BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of...
03. August 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results

-- Appointed David Meeker, M.D., as President and Chief Executive Officer – -- FDA granted rare pediatric disease designations for setmelanotide for the treatment of POMC and LEPR...
27. Juli 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations

BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of...
20. Juli 2020 07:30 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of...
16. Juli 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism

-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm...
01. Juli 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities

-- Company also announces positive data from eight supplemental patients, including four pediatric patients, enrolled in pivotal Phase 3 clinical trials; all achieved primary endpoint of 10 percent...
01. Juli 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities

BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of...
24. Juni 2020 08:00 ET | Quelle: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Positive Results from Phase 2 Study of Once-weekly Formulation of Setmelanotide in Healthy Obese Volunteers

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation – -- Both weekly and daily formulations of setmelanotide were observed to be safe and...

Vorherige Seite